Cristina Enjuanes1, Jordi Bruguera2, María Grau3, Mercé Cladellas4, Gina Gonzalez5, Oona Meroño6, Pedro Moliner-Borja2, José M Verdú7, Nuria Farré2, Josep Comín-Colet8. 1. Programa de Insuficiencia Cardiaca, Servicio de Cardiología, Hospital del Mar, Barcelona, Spain; Grupo de Investigación Biomédica en Enfermedades del Corazón, IMIM (Instituto Hospital del Mar de Investigaciones Médicas), Barcelona, Spain; Departmento de Medicina, Universidad Autónoma de Barcelona, Barcelona, Spain. Electronic address: cristinaenjuanes@gmail.com. 2. Programa de Insuficiencia Cardiaca, Servicio de Cardiología, Hospital del Mar, Barcelona, Spain; Grupo de Investigación Biomédica en Enfermedades del Corazón, IMIM (Instituto Hospital del Mar de Investigaciones Médicas), Barcelona, Spain. 3. Grupo de Epidemiología y Genética Cardiovascular, IMIM (Instituto Hospital del Mar de Investigaciones Médicas), Barcelona, Spain. 4. Grupo de Investigación Biomédica en Enfermedades del Corazón, IMIM (Instituto Hospital del Mar de Investigaciones Médicas), Barcelona, Spain; Departmento de Medicina, Universidad Autónoma de Barcelona, Barcelona, Spain. 5. Programa de Insuficiencia Cardiaca, Servicio de Cardiología, Hospital del Mar, Barcelona, Spain. 6. Grupo de Investigación Biomédica en Enfermedades del Corazón, IMIM (Instituto Hospital del Mar de Investigaciones Médicas), Barcelona, Spain. 7. Grupo de Investigación Biomédica en Enfermedades del Corazón, IMIM (Instituto Hospital del Mar de Investigaciones Médicas), Barcelona, Spain; Instituto de Investigación en Atención Primaria Jordi Gol, Instituto Catalán de la Salud, Barcelona, Spain. 8. Programa de Insuficiencia Cardiaca, Servicio de Cardiología, Hospital del Mar, Barcelona, Spain; Grupo de Investigación Biomédica en Enfermedades del Corazón, IMIM (Instituto Hospital del Mar de Investigaciones Médicas), Barcelona, Spain; Departmento de Medicina, Universidad Autónoma de Barcelona, Barcelona, Spain.
Abstract
INTRODUCTION AND OBJECTIVES: To evaluate the effect of iron deficiency and anemia on submaximal exercise capacity in patients with chronic heart failure. METHODS: We undertook a single-center cross-sectional study in a group of stable patients with chronic heart failure. At recruitment, patients provided baseline information and completed a 6-minute walk test to evaluate submaximal exercise capacity and exercise-induced symptoms. At the same time, blood samples were taken for serological evaluation. Iron deficiency was defined as ferritin < 100 ng/mL or transferrin saturation < 20% when ferritin is < 800 ng/mL. Additional markers of iron status were also measured. RESULTS: A total of 538 heart failure patients were eligible for inclusion, with an average age of 71 years and 33% were in New York Heart Association class III/IV. The mean distance walked in the test was 285 ± 101 meters among those with impaired iron status, vs 322 ± 113 meters (P=.002). Symptoms during the test were more frequent in iron deficiency patients (35% vs 27%; P=.028) and the most common symptom reported was fatigue. Multivariate logistic regression analyses showed that increased levels of soluble transferrin receptor indicating abnormal iron status were independently associated with advanced New York Heart Association class (P < .05). Multivariable analysis using generalized additive models, soluble transferrin receptor and ferritin index, both biomarkers measuring iron status, showed a significant, independent and linear association with submaximal exercise capacity (P=.03 for both). In contrast, hemoglobin levels were not significantly associated with 6-minute walk test distance in the multivariable analysis. CONCLUSIONS: In patients with chronic heart failure, iron deficiency but not anemia was associated with impaired submaximal exercise capacity and symptomatic functional limitation.
INTRODUCTION AND OBJECTIVES: To evaluate the effect of iron deficiency and anemia on submaximal exercise capacity in patients with chronic heart failure. METHODS: We undertook a single-center cross-sectional study in a group of stable patients with chronic heart failure. At recruitment, patients provided baseline information and completed a 6-minute walk test to evaluate submaximal exercise capacity and exercise-induced symptoms. At the same time, blood samples were taken for serological evaluation. Iron deficiency was defined as ferritin < 100 ng/mL or transferrin saturation < 20% when ferritin is < 800 ng/mL. Additional markers of iron status were also measured. RESULTS: A total of 538 heart failurepatients were eligible for inclusion, with an average age of 71 years and 33% were in New York Heart Association class III/IV. The mean distance walked in the test was 285 ± 101 meters among those with impairediron status, vs 322 ± 113 meters (P=.002). Symptoms during the test were more frequent in iron deficiencypatients (35% vs 27%; P=.028) and the most common symptom reported was fatigue. Multivariate logistic regression analyses showed that increased levels of soluble transferrin receptor indicating abnormal iron status were independently associated with advanced New York Heart Association class (P < .05). Multivariable analysis using generalized additive models, soluble transferrin receptor and ferritin index, both biomarkers measuring iron status, showed a significant, independent and linear association with submaximal exercise capacity (P=.03 for both). In contrast, hemoglobin levels were not significantly associated with 6-minute walk test distance in the multivariable analysis. CONCLUSIONS: In patients with chronic heart failure, iron deficiency but not anemia was associated with impaired submaximal exercise capacity and symptomatic functional limitation.
Keywords:
6-minute walk test; Capacidad de ejercicio submáxima; Déficit de hierro; Heart failure; Insuficiencia cardiaca; Iron deficiency; Prueba de 6 minutos de marcha; Receptor de transferrina soluble; Soluble transferrin receptor; Submaximal exercise capacity
Authors: Rik Paulus Bernardus Tonino; Michael Wilson; Jaap Jan Zwaginga; Martin Roelof Schipperus Journal: Vox Sang Date: 2021-08-24 Impact factor: 2.996
Authors: Maria Domenica Cappellini; Josep Comin-Colet; Angel de Francisco; Axel Dignass; Wolfram Doehner; Carolyn S Lam; Iain C Macdougall; Gerhard Rogler; Clara Camaschella; Rezan Kadir; Nicholas J Kassebaum; Donat R Spahn; Ali T Taher; Khaled M Musallam Journal: Am J Hematol Date: 2017-07-07 Impact factor: 10.047
Authors: Alex Alcaide-Aldeano; Alberto Garay; Lídia Alcoberro; Santiago Jiménez-Marrero; Sergi Yun; Marta Tajes; Elena García-Romero; Carles Díez-López; José González-Costello; Gemma Mateus-Porta; Miguel Cainzos-Achirica; Cristina Enjuanes; Josep Comín-Colet; Pedro Moliner Journal: J Clin Med Date: 2020-04-22 Impact factor: 4.241